Cancer metabolism and drug resistance

Mahbuba Rahman, Mohammad Rubayet Hasan

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs.

Original languageEnglish
Pages (from-to)571-600
Number of pages30
JournalMetabolites
Volume5
Issue number4
DOIs
Publication statusPublished - 30 Sep 2015

Fingerprint

Drug Resistance
Metabolism
Cells
Pharmaceutical Preparations
Neoplasms
Oncology
Nutrients
Throughput
Fluxes
Metabolic Networks and Pathways
Molecules
Enzymes
Metabolic Flux Analysis
Metabolomics
Systems Biology
Epigenomics
Proteomics
Research Personnel
Technology
Phenotype

Keywords

  • Antimetabolites
  • Drug resistance
  • Metabolic flux analysis
  • Metabolic pathways
  • Systems biology
  • Targeted therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology

Cite this

Cancer metabolism and drug resistance. / Rahman, Mahbuba; Hasan, Mohammad Rubayet.

In: Metabolites, Vol. 5, No. 4, 30.09.2015, p. 571-600.

Research output: Contribution to journalReview article

Rahman, Mahbuba ; Hasan, Mohammad Rubayet. / Cancer metabolism and drug resistance. In: Metabolites. 2015 ; Vol. 5, No. 4. pp. 571-600.
@article{28d2eb81c6c34b4c9a94cebdc168343c,
title = "Cancer metabolism and drug resistance",
abstract = "Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs.",
keywords = "Antimetabolites, Drug resistance, Metabolic flux analysis, Metabolic pathways, Systems biology, Targeted therapy",
author = "Mahbuba Rahman and Hasan, {Mohammad Rubayet}",
year = "2015",
month = "9",
day = "30",
doi = "10.3390/metabo5040571",
language = "English",
volume = "5",
pages = "571--600",
journal = "Metabolites",
issn = "2218-1989",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Cancer metabolism and drug resistance

AU - Rahman, Mahbuba

AU - Hasan, Mohammad Rubayet

PY - 2015/9/30

Y1 - 2015/9/30

N2 - Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs.

AB - Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be associated with the etiology of cancer. Furthermore, accumulating evidence suggest that cancer metabolism is intimately linked to drug resistance, which is currently one of the most important challenges in cancer treatment. Altered metabolic pathways help cancer cells to proliferate at a rate higher than normal, adapt to nutrient limited conditions, and develop drug resistance phenotypes. Application of systems biology, boosted by recent advancement of novel high-throughput technologies to obtain cancer-associated, transcriptomic, proteomic and metabolomic data, is expected to make a significant contribution to our understanding of metabolic properties related to malignancy. Indeed, despite being at a very early stage, quantitative data obtained from the omics platforms and through applications of 13C metabolic flux analysis (MFA) in in vitro studies, researchers have already began to gain insight into the complex metabolic mechanisms of cancer, paving the way for selection of molecular targets for therapeutic interventions. In this review, we discuss some of the major findings associated with the metabolic pathways in cancer cells and also discuss new evidences and achievements on specific metabolic enzyme targets and target-directed small molecules that can potentially be used as anti-cancer drugs.

KW - Antimetabolites

KW - Drug resistance

KW - Metabolic flux analysis

KW - Metabolic pathways

KW - Systems biology

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85006201112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006201112&partnerID=8YFLogxK

U2 - 10.3390/metabo5040571

DO - 10.3390/metabo5040571

M3 - Review article

AN - SCOPUS:85006201112

VL - 5

SP - 571

EP - 600

JO - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 4

ER -